Release Date: 21 July 2024
Fruquintinib, developed by HUTCHMED, is a highly selective oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. This potent small molecule has shown promise in treating various solid tumors....
Release Date: 21 July 2024
Trilaciclib, developed by G1 Therapeutics, has made significant strides in cancer treatment as a novel CDK4/6 inhibitor. Administered intravenously before chemotherapy, it aims to reduce chemotherapy-induced myelosuppress...
Release Date: 21 July 2024
Gumarontinib, co-developed by Haihe Biopharma and Shanghai Institute of Material Medica, is an innovative oral mesenchymal-epithelial transition (MET) proto-oncogene inhibitor. In March 2023, it achieved a significant mil...
Release Date: 21 July 2024
Benmelstobart, a novel fully humanized anti-PD-L1 monoclonal antibody developed by Chia Tai Tianqing Pharmaceutical, has demonstrated significant achievements in cancer treatment. In April 2022, it received breakthrough t...
Release Date: 21 July 2024
Selinexor, developed by Karyopharm Therapeutics, is a groundbreaking oral Selective Inhibitor of Nuclear Export (SINE) compound. It works by inhibiting the nuclear export protein exportin 1 (XPO1). In July 2019, the FDA a...
Release Date: 20 July 2024
Aumolertinib, developed by Hansoh Pharmaceutical, is a pioneering third-generation, irreversible EGFR-TKI designed to selectively inhibit both EGFR sensitizing and resistance mutations. This innovative drug has gained app...
Release Date: 20 July 2024
Toripalimab, marketed as Tuoyi in China and Loqtorzi in the US, is a next-generation anti-PD-1 monoclonal antibody developed by Shanghai Junshi Biosciences. This innovative immunotherapy blocks PD-L1 binding to PD-1 at a ...
Release Date: 20 July 2024
Serplulimab, marketed as Hansizhuang, is a groundbreaking recombinant humanized anti-PD-1 monoclonal antibody developed by Shanghai Henlius Biotech. Launched in China in March 2022, it has gained approval for treating var...
Release Date: 20 July 2024
Utidelone, also known as Depoxythilone, is an innovative epothilone B analogue developed by Beijing Biostar Pharmaceuticals. This genetically engineered compound functions as a novel microtubule stabilizing agent, offerin...
Release Date: 20 July 2024
Mimeixin, developed by Luye Pharma Group, is an innovative pain management solution combining oxycodone hydrochloride and naloxone hydrochloride dihydrate. Approved by China’s National Medical Products Administratio...
Release Date: 19 July 2024
More Than 2500 Cancer Drugs Are In Clinical Trials In China Says Kuick Research
Read More
Release Date: 18 July 2024
Penpulimab, marketed as Anniko, is an innovative monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. Developed through a collaboration between Akeso and Chia Tai Tianqing, this immunotherapy...
Release Date: 18 July 2024
Belzutifan, marketed as Welireg, is a groundbreaking selective inhibitor of hypoxia-inducible factor 2 alpha (HIF-2 alpha). Initially developed by Peloton Therapeutics, it was later acquired by Merck in 2019. This innovat...
Release Date: 18 July 2024
Envafolimab is a pioneering single domain anti-PD-L1 antibody developed by Alphamab Oncology. In November 2021, it received approval from China’s NMPA for treating adult patients with MSI-H or dMMR advanced solid tu...
Release Date: 18 July 2024
Tucidinostat, also known as Chidamide, is a pioneering cancer treatment developed by Chipscreen Biosciences. It is the first oral subtype-selective histone deacetylase (HDAC) inhibitor, specifically targeting certain HDAC subtypes to address abnormal...